A phase I clinical trial of human embryonic stem cell-derived retinal pigment epithelial cells for early-stage Stargardt macular degeneration: 5-years' follow-up.
Shi-Ying LiYong LiuLei WangFang WangTong-Tao ZhaoQi-You LiHai-Wei XuXiao-Hong MengJie HaoQi ZhouLiu WangZheng-Qin YinPublished in: Cell proliferation (2021)
Subretinal transplantation of hESC-RPE in early-stage STGD1 is safe and tolerated in the long term. Further investigation is needed for choosing proper subjects according to the multi-model image and function assessments.
Keyphrases
- early stage
- stem cells
- clinical trial
- endothelial cells
- sentinel lymph node
- optical coherence tomography
- deep learning
- induced pluripotent stem cells
- diabetic retinopathy
- cell therapy
- pluripotent stem cells
- phase ii
- machine learning
- lymph node
- radiation therapy
- squamous cell carcinoma
- cataract surgery
- mesenchymal stem cells
- neoadjuvant chemotherapy